Drug Trial Radar · NCT03097796
A Multiple Ascending Dose Study of PUL-042 in Stem Cell Transplant Recipients
Last checked: Nov 19, 2026Latest source record: Apr 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Dec 2024
Primary completion
Mar 2026
Study completion May 2026
Sponsor
- Lead sponsor
- Pulmotect, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- National Heart, Lung, and Blood Institute (NHLBI); Cancer Prevention Research Institute of Texas
- First posted
- Mar 31, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Subjects with hematologic malignancies or recipients of a first allogenic or autologus hematopoietic stem cell transplant, without any evidence or respiratory infection, will receive 4 doses of PUL-042 Inhalation Solution over a 2 week period. Subjects will be evaluated for tolerability of the drug. If tolerated, dose escalation may occur with up to 4 dose levels tested
Conditions
- Hematologic Diseases
- Stem Cell Transplants
Interventions
PUL-042Drug
PUL-042 Inhalation Solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Forced Expiratory Volume in one Second (FEV1)Time frame: 3 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Texas MD Anderson MD Anderson Cancer Center
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.